Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Ekso Bionics Holdings's Debt-to-EBITDA or its related term are showing as below:
EKSO'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.63 Med: -0.33 Max: -0.2
Current: -0.32
During the past 13 years, the highest Debt-to-EBITDA Ratio of Ekso Bionics Holdings was -0.20. The lowest was -0.63. And the median was -0.33.
EKSO's Debt-to-EBITDA is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 1.6
vs EKSO: -0.32
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Ekso Bionics Holdings Debt-to-EBITDA Related Terms
Ekso Bionics Holdings Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Ekso Bionics Holdings's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EKSO vs POCI, HBIO, NEPH: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Ekso Bionics Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ekso Bionics Holdings Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ekso Bionics Holdings's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ekso Bionics Holdings's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Ekso Bionics Holdings (EKSO) has a Debt-to-EBITDA of -0.17 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Ekso Bionics Holdings.
Is Ekso Bionics Holdings' Debt-to-EBITDA too high?
Ekso Bionics Holdings' current Debt-to-EBITDA is -0.17. Overall, Ekso Bionics Holdings has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Ekso Bionics Holdings' Debt-to-EBITDA compare to POCI and HBIO?
Ekso Bionics Holdings' Debt-to-EBITDA of -0.17 can be compared against companies in the Medical Devices & Instruments industry. The industry median Debt-to-EBITDA is 1.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.60, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Ekso Bionics Holdings. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ekso Bionics Holdings's current Debt-to-EBITDA is -0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ekso Bionics Holdings stock overvalued right now?
Ekso Bionics Holdings (EKSO) has a current Debt-to-EBITDA of -0.17. The stock's GF Value™ is $4.40, compared to a current price of $11.65 — trading 164.8% above its estimated fair value. The current Debt-to-EBITDA is -0.17. Ekso Bionics Holdings' overall GF Score™ is 32/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Ekso Bionics Holdings (EKSO), the current Debt-to-EBITDA is -0.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ekso Bionics Holdings (EKSO) Overvalued in 2026?
Based on GuruFocus' analysis, Ekso Bionics Holdings stock appears to be overvalued.
The current stock price of $11.65 is trading 164.8% above its estimated GF Value™ of $4.40.
Key valuation signals for EKSO:
Debt-to-EBITDA: -0.17
GF Value™: $4.40 vs. price of $11.65 (164.8% above fair value)
No single metric tells the full story. See the EKSO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
32GF Score
Get the complete analysis for EKSO
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EKSO has been successfully added to your 
